Percutaneous Transcatheter Aortic Valve Implantation
- 1 May 2010
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Cardiology in Review
- Vol. 18 (3), 111-124
- https://doi.org/10.1097/crd.0b013e3181c42627
Abstract
Surgical aortic valve replacement remains the gold standard for the treatment of severe, symptomatic aortic stenosis. However, percutaneous treatments are challenging this paradigm in high-risk surgical patients. Technological developments have been rapid in the field of percutaneous aortic valve intervention. Two devices have been approved for general use in Europe: the Edwards SAPIEN™ valve (Edwards Lifesciences, Irvine, CA) and the CoreValve ReValving® System (CoreValve ReValving® Technology Medtronic Inc., Minneapolis, MN), with 15 potential new designs for percutaneous aortic valves in development around the world. Both systems can be delivered via the transfemoral, transapical and the axillary/subclavian routes, depending upon patient characteristics, anatomy, and the device available to the operator. Careful selection of appropriate patients is essential to ensure a safe procedure. This necessitates a multidisciplinary approach, with multiple imaging modalities used to fully delineate the peripheral vasculature, aortic anatomy and the valve itself. It is important to remember, however, that just because we can treat aortic valve disease percutaneously, it does not mean that we necessarily should. The gold standard treatment for aortic stenosis remains thoracotomy and surgical replacement of the valve; to this end it is essential that surgeons play a central role in the decision-making processes for transcatheter aortic valve implantation and that they embrace this new and exciting technology, which promises to dramatically change the way their high-risk aortic valve patients are managed over the course of the next 10 years.Keywords
This publication has 69 references indexed in Scilit:
- Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI)European Heart Journal, 2008
- Aortic valve surgery in octogenarians: predictive factors for operative and long-term resultsEuropean Journal of Cardio-Thoracic Surgery, 2007
- Clinical Profile and Natural History of 453 Nonsurgically Managed Patients With Severe Aortic StenosisThe Annals of Thoracic Surgery, 2006
- ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart DiseaseJournal of the American College of Cardiology, 2006
- Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?European Heart Journal, 2005
- Hospital Volume and Surgical Mortality in the United StatesNew England Journal of Medicine, 2002
- Mortality after aortic valve replacement: results from a nationally representative databaseThe Annals of Thoracic Surgery, 2000
- Observed and relative survival after aortic valve replacementJournal of the American College of Cardiology, 2000
- Porcine bioprostheses in the elderly: Clinical performance by age groups and valve positionsThe Annals of Thoracic Surgery, 1995
- Aortic StenosisCell Metabolism, 1968